Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)

Assesses therapeutic potential of escitalopram in managing certain behavioral symptoms of Alzheimer’s disease.
Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)

More Details About the Study

What is the S-CitAD study about?

The S-CitAD study for Agitation in Alzheimer’s is being done to see if escitalopram can safely reduce symptoms of agitation and aggression in AD.

Am I eligible to participate?

We are enrolling individuals who have:

  • A diagnosis of Alzheimer’s disease
  • Frequent agitation or aggression
  • A caregiver or study partner who spends time with them and can accompany them on study visits

Why should I participate?

Participants and caregivers receive counseling and materials to manage agitation.

Share this study


More studies


The next phase of Alzheimer’s Disease Neuroimaging Initiative (ADNI) research, ADNI4 is now recruiting participants with or without memory issues to help us continue investigating important questions concerning early detection of mild cognitive impairment and Alzheimer’s Disease.

Read more »
Skip to content